Q1 2026 Ashland Inc Earnings Call Transcript
Key Points
- Ashland Inc (ASH) delivered solid results in the first quarter despite ongoing demand softness in coatings and construction, supported by strong execution and disciplined cost actions.
- Life sciences segment showed healthy growth, driven by resilient pharma demand and momentum across innovative and globalized pillars.
- Personal care segment delivered stable performance, with biofunctional actives growing double digits and microbial protection gaining market share.
- Specialty additives segment achieved meaningful margin expansion despite lower volumes, thanks to cost actions and HCC network benefits.
- Ashland Inc (ASH) demonstrated strong operational discipline and delivered strong operating cash flow, with $125 million of cash provided by operating activities.
- Specialty additives segment faced muted demand, with coatings and construction driving most of the year-over-year decline.
- Intermediate market conditions were softer, reflecting trough-like dynamics across BDO and its derivatives, which pressured captive BDO transfer pricing.
- The Calvert City equipment replacement issue impacted costs and pressured margins, with the impact extending into the second quarter.
- Recent weather-related events in the Mid-Atlantic impacted operations, resulting in incremental costs.
- Sales for the quarter were down 5% versus last year, with a mixed demand environment and modest pricing pressure.
Hello, and thank you for standing by. Welcome to Ashland's first-quarter 2026 earnings conference call and webcast. (Operator Instructions)
I would now like to hand the conference over to Sandy Klugman, Director of Investor Relations. You may begin.
Thank you. Hello, everyone. Welcome to Ashland's first quarter fiscal year 2026 earnings conference call and webcast. My name is Sandy Klugman, and I'm Ashland's Director of Investor Relations. Joining me on the call today are Guillermo Novo, Chair and CEO, William Whitaker, CFO, as well as our business unit leaders, Alessandra Facine, Life Sciences and Intermediates, Jim Minicucci, Personal Care, and Dago Caceres, Specialty Additives. Please note that we will be referencing slides during today's call. We encourage you to follow along with the webcast materials available at ashland.com under investor relations. As a reminder, today's presentation aims forward-looking statements regarding our fiscal 2026 outlook and other matters, as detailed on slide
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
